SCHEDULE 13G: BlackRock Discloses 5.3% Stake in INHIBRX BIOSCIENCES

BlackRock, Inc. has filed a Schedule 13G, reporting a 5.3% beneficial ownership stake in INHIBRX BIOSCIENCES, INC. as of December 31, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 768,130 shares of common stock in INHIBRX BIOSCIENCES, INC.
• This stake represents 5.3% of the total outstanding common stock of INHIBRX BIOSCIENCES, INC.
• BlackRock holds sole voting power over 759,521 shares and sole dispositive power over 768,130 shares.
• The filing was made under Rule 13d-1(b), indicating a passive investment where BlackRock does not intend to influence or change control of the issuer.
• The securities were acquired and are held in the ordinary course of business.
• Several BlackRock subsidiaries, including BlackRock Advisors, LLC and BlackRock Fund Advisors, are involved in the beneficial ownership.

Sentiment

Score: 6

Explanation: The filing indicates a significant, passive investment by BlackRock, a major institutional investor, in INHIBRX BIOSCIENCES, INC. While not an active endorsement of management or strategy, a substantial stake from such an entity is generally viewed as a positive signal of confidence in the company's long-term prospects, albeit without any explicit forward-looking statements or operational details.

Positives

• A significant 5.3% stake by a major institutional investor like BlackRock can be interpreted as a vote of confidence in INHIBRX BIOSCIENCES, INC.'s long-term prospects.
• The passive nature of the investment (Rule 13d-1(b)) suggests BlackRock is not seeking to influence management or control, which can provide stability to the company's governance.

Future Outlook

The filing is a disclosure of current ownership and does not contain any forward-looking statements or guidance regarding INHIBRX BIOSCIENCES, INC. or BlackRock's future investment intentions beyond the passive nature of the current holding.

Management Comments

• To the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

This filing reflects a standard institutional investment disclosure. Large asset managers like BlackRock routinely acquire significant, passive stakes in publicly traded companies as part of their diversified investment strategies for various funds and clients. The 5.3% stake in INHIBRX BIOSCIENCES, INC. indicates it has met BlackRock's investment criteria for inclusion in certain portfolios.

Comparison to Industry Standards

• Not applicable. This filing is a disclosure of an ownership stake by a large institutional investor, BlackRock, in INHIBRX BIOSCIENCES, INC. It does not present financial results or operational performance that can be directly compared to industry benchmarks or specific comparable companies/projects.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a stake might instill confidence among existing shareholders and potentially attract new investors.
• Management: The passive nature of BlackRock's investment suggests no immediate pressure or influence on INHIBRX BIOSCIENCES, INC. management or strategic direction from this particular shareholder.

Key Dates

Recommendation

The filing indicates a significant, passive stake by BlackRock, a major institutional investor. While this is generally a positive signal, the filing itself provides no new operational or financial data about INHIBRX BIOSCIENCES, INC. to warrant a 'buy' or 'sell' recommendation. It simply confirms a large, passive institutional presence. Investors should 'hold' and await further operational updates or financial results from the company to make a more informed decision.

Keywords

INHIBRX BIOSCIENCES, BlackRock, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Passive Investment, Equity Stake, SEC Filing